Clinical Trial Update: Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial of CP-751,871 in combination with docetaxel for advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN